Organization
Taizhou Mabtech Pharmaceutical
9 clinical trials
1 abstract
Clinical trial
Phase I Comparison of Pharmacokinetics, Safety, and Immunogenicity of CMAB015 Injection and Cosentyx in a Randomized, Double-blind, Parallel Controlled, Single-dose Study in Healthy Chinese Male SubjectsStatus: Completed, Estimated PCD: 2023-07-03
Clinical trial
A Randomized, Double-blind, Parallel Controlled, Phase I Three-arm Study, Comparing the PK, PD, Safety, and Immunogenicity of Pre- and Post-change CMAB807X, Post-change CMAB807X and Xgeva® in Healthy Chinese Male SubjectsStatus: Withdrawn, Estimated PCD: 2024-06-01
Clinical trial
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Terminated, Estimated PCD: 2023-10-16
Clinical trial
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease PatientsStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Positive Parallel Controlled Phase III Clinical Trial to Compare Omalizumab α(CMAB007) and Xolair® in Patients With Chronic Spontaneous UrticariaStatus: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
Open, Randomized, Controlled, Multicenter Phase III Study Comparing CMAB009 Plus FOLFIRI Versus FOLFIRI Alone as First-line Treatment for Epidermal Growth Factor Receptor-expressing, RAS/BRAF Wild-type, Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2022-05-06
Clinical trial
A Randomized, Double-blind, Parallel Controlled, Phase I Study, Comparing the PK, PD, Safety, and Immunogenicity of Post-change CMAB807and Prolia in Healthy Chinese SubjectsStatus: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
Phase I Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of CMAB007 and Xolair in a Randomized, Double-blind, Parallel Controlled, Single-dose Study in Healthy Chinese Male SubjectsStatus: Completed, Estimated PCD: 2022-06-27
Abstract
High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.Org: Zhejiang Cancer Hospital, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group, Zhejiang Hospital, Department of Thoracic Medical Oncology,
Clinical trial
Comparative Study of the Efficacy, Safety, and Immunogenicity of CMAB015 and Secukinumab in Adult Patients With Moderate-severe Chronic Plaque PsoriasisStatus: Not yet recruiting, Estimated PCD: 2025-05-31